The effect of consuming the liposomal form of pistachio kernel oil on multiple sclerosis

Comparison of the effect of liposomal form of pistachio kernel oil and placebo on the level of some inflammatory and anti-inflammatory agents as well as their receptors in mononuclear cells in peripheral blood and change in the severity of clinical symptoms in women with multiple sclerosis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201219049765N1

Enrollment

500

Registered

2021-08-04

Start date

2021-08-19

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis (MS). Multiple sclerosis

Interventions

Intervention 1: Intervention group: once a day, 5 ml, liposomal form of 10% pistachio kernel oil, orally, for 24 weeks. In this study, no special equipment is used and the explanations of this trial a

Eligibility

Sex/Gender

Female

Age

18 Years to 51 Years

Inclusion criteria

Inclusion criteria: Women aged 18 to 51 years Definite diagnosis of multiple sclerosis with a descriptive measure of disability rate between 1 to 3

Exclusion criteria

Exclusion criteria: Taking corticosteroids during the study Pregnancy and lactation Active cardiovascular disease, liver disease, gastrointestinal disease, patients with Helicobacter pylori positive test, kidney disease, diabetes mellitus, respiratory disease and autoimmune diseases Take multivitamin, mineral, antioxidant and pistachio kernel supplements during the 30 days before the study

Design outcomes

Primary

Measure	Time frame
Concentration of inflammatory and anti-inflammatory factors. Timepoint: Intervention time (w0), 6 weeks after intervention (w6), 12 weeks after intervention (w12), 18 weeks after intervention (w18) and 24 weeks after intervention (w24). Method of measurement: With ELISA Kit.;Relative expression of genes of receptors of inflammatory and anti-inflammatory agents. Timepoint: Intervention time (w0), 24 weeks after intervention (w24). Method of measurement: By Realtime PCR.;The length and severity of the disease. Timepoint: Intervention time (w0), 6 weeks after intervention (w6), 12 weeks after intervention (w12), 18 weeks after intervention (w18) and 24 weeks after intervention (w24). Method of measurement: According to the descriptive measurement of disability rate.	—

Measure

Time frame

Concentration of inflammatory and anti-inflammatory factors. Timepoint: Intervention time (w0), 6 weeks after intervention (w6), 12 weeks after intervention (w12), 18 weeks after intervention (w18) and 24 weeks after intervention (w24). Method of measurement: With ELISA Kit.;Relative expression of genes of receptors of inflammatory and anti-inflammatory agents. Timepoint: Intervention time (w0), 24 weeks after intervention (w24). Method of measurement: By Realtime PCR.;The length and severity of the disease. Timepoint: Intervention time (w0), 6 weeks after intervention (w6), 12 weeks after intervention (w12), 18 weeks after intervention (w18) and 24 weeks after intervention (w24). Method of measurement: According to the descriptive measurement of disability rate.

—

Secondary

Measure	Time frame
Allergies to pistachio compounds. Timepoint: Intervention time (w0), 6 weeks after intervention (w6), 12 weeks after intervention (w12), 18 weeks after intervention (w18) and 24 weeks after intervention (w24). Method of measurement: Qualitative examination with patient self-declaration.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Gholam Hossein Hassan Shahi

Rafsanjan University of Medical Sciences

alijebal2011@gmail.com+98 34 3428 0038

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026